Identifying Predictive Risk Factors for Future Cognitive Impairment Among Chinese Older Adults: Longitudinal Prediction Study DOI Creative Commons
Collin Sakal, Tingyou Li, Juan Li

et al.

JMIR Aging, Journal Year: 2024, Volume and Issue: 7, P. e53240 - e53240

Published: March 22, 2024

Abstract Background The societal burden of cognitive impairment in China has prompted researchers to develop clinical prediction models aimed at making risk assessments that enable preventative interventions. However, it is unclear what types factors best predict future impairment, if known make equally accurate predictions across different socioeconomic groups, and existing are subpopulations. Objective This paper identify which domain health information predicts among Chinese older adults examine discrepancies exist predictive ability population subsets. Methods Using data from the Longitudinal Healthy Longevity Survey, we quantified demographics, instrumental activities daily living, tests, social hobbies, psychological factors, diet, exercise sleep, chronic diseases, 3 recently published logistic regression–based 3-year general male, female, rural-dwelling, urban-dwelling, educated, not formally educated adults. Predictive was using area under receiver operating characteristic curve (AUC) sensitivity-specificity curves through 20 repeats 10-fold cross-validation. Results A total 4047 participants were included study, 337 (8.3%) developed years after baseline collection. factor groups with demographics (AUC 0.78, 95% CI 0.77-0.78), tests 0.72, 0.72-0.73), living 0.71, 0.70-0.71). Demographics, all recreated had significantly higher AUCs when female compared male no formal education those some education. Conclusions study suggests most useful for predicting have lower power More efforts needed ensure can be conducted China.

Language: Английский

Biomarker Changes during 20 Years Preceding Alzheimer’s Disease DOI
Jianping Jia, Yuye Ning, Meiling Chen

et al.

New England Journal of Medicine, Journal Year: 2024, Volume and Issue: 390(8), P. 712 - 722

Published: Feb. 21, 2024

Biomarker changes that occur in the period between normal cognition and diagnosis of sporadic Alzheimer's disease have not been extensively investigated longitudinal studies.

Language: Английский

Citations

151
Aggregation-Induced Emission Luminogen: Role in Biopsy for Precision Medicine DOI Creative Commons
Yanhong Duo, Lei Han, Yaoqiang Yang

et al.

Chemical Reviews, Journal Year: 2024, Volume and Issue: 124(20), P. 11242 - 11347

Published: Oct. 9, 2024

Biopsy, including tissue and liquid biopsy, offers comprehensive real-time physiological pathological information for disease detection, diagnosis, monitoring. Fluorescent probes are frequently selected to obtain adequate on processes in a rapid minimally invasive manner based their advantages biopsy. However, conventional fluorescent have been found show aggregation-caused quenching (ACQ) properties, impeding greater progresses this area. Since the discovery of aggregation-induced emission luminogen (AIEgen) promoted advancements molecular bionanomaterials owing unique high quantum yield (QY) signal-to-noise ratio (SNR),

Language: Английский

Citations

18
Blood phosphorylated Tau181 reliably differentiates amyloid‐positive from amyloid‐negative subjects in the Alzheimer's disease continuum: A systematic review and meta‐analysis DOI Creative Commons
Annibale Antonioni,

Emanuela Maria Raho,

Lamberto Manzoli

et al.

Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring, Journal Year: 2025, Volume and Issue: 17(1)

Published: Jan. 1, 2025

Abstract INTRODUCTION Blood‐based biomarkers seem promising for the diagnosis of Alzheimer's disease (AD). METHODS We performed a systematic review and meta‐analysis on potential blood phosphorylated Tau181 (p‐tau181) to differentiate amyloid‐positive (A+) amyloid‐negative (A−) subjects. Two meta‐analyses were conducted, showing mean p‐tau values in cerebrospinal fluid (CSF) A+ A− group, second comparing concentrations CSF among versus A‐ participants, by laboratory assessment method. RESULTS Eighteen studies (2764 5646 subjects) included. The single‐group showed higher p‐tau181 than group. In head‐to‐head meta‐analysis, reliably differentiated patients from participants. DISCUSSION Regardless technique, differentiates Therefore, it might have important applications early inclusion clinical trials AD patients. Highlights role blood‐based discriminating is still uncertain. Blood distinguishes allow trials.

Language: Английский

Citations

5
Artificial intelligence for dementia—Applied models and digital health DOI Creative Commons
Donald M. Lyall, Andrey Kormilitzin, Claire Lancaster

et al.

Alzheimer s & Dementia, Journal Year: 2023, Volume and Issue: 19(12), P. 5872 - 5884

Published: July 26, 2023

Abstract INTRODUCTION The use of applied modeling in dementia risk prediction, diagnosis, and prognostics will have substantial public health benefits, particularly as “deep phenotyping” cohorts with multi‐omics data become available. METHODS This narrative review synthesizes understanding models digital technologies, terms diagnostic discrimination, prognosis, progression. Machine learning approaches show evidence improved predictive power compared to standard clinical scores predicting dementia, the potential decompose large numbers variables into relatively few critical predictors. RESULTS focuses on key areas emerging promise including: emphasis easier, more transparent sharing cohort access; integration high‐throughput biomarker electronic record modeling; progressing beyond primary prediction secondary outcomes, for example, treatment response physical health. DISCUSSION Such benefit also from improvements remote measurement, whether cognitive (e.g., online), or naturalistic watch‐based accelerometry).

Language: Английский

Citations

25
Blood-based biomarkers for Alzheimer’s disease: a multicenter-based cross-sectional and longitudinal study in China DOI Creative Commons
Feng Gao, Linbin Dai, Qiong Wang

et al.

Science Bulletin, Journal Year: 2023, Volume and Issue: 68(16), P. 1800 - 1808

Published: July 11, 2023

Discrepancies in diagnostic biomarkers for Alzheimer's Disease (AD) may arise from racial disparities, risk factors, or lifestyle differences. Moreover, there has been a lack of systematic and multicenter studies to evaluate baselines the AD Chinese populations. Thus, is an urgent need research investigate effectiveness blood AD, specifically Han population, using approach. In present multicenter-based cross-sectional longitudinal study, we evaluated 817 samples 6 different clinical centers. We measured plasma amyloid beta (Aβ)-40, Aβ42, phosphorylated tau 181 (pTau), total (tTau), serum neurofilament light (NFL), glial fibrillary acidic protein (GFAP). Additionally, 18F-florbetapir positron electron tomography magnetic resonance imaging were also performed. A combination APOE genotype with pTau GFAP demonstrated exceptional performance distinguishing Aβ status. Furthermore, baseline levels exhibited strong association cognitive decline over time brain atrophy, higher predicting faster rate neurodegeneration. summary, these results validate practicality encompassing various regions within China. they emphasize potential as non-invasive methods detecting screening at early stage.

Language: Английский

Citations

24
Changes in CSF sPDGFRβ level and their association with blood–brain barrier breakdown in Alzheimer’s disease with or without small cerebrovascular lesions DOI Creative Commons

Xinyi Lv,

Mengguo Zhang,

Zhaozhao Cheng

et al.

Alzheimer s Research & Therapy, Journal Year: 2023, Volume and Issue: 15(1)

Published: March 14, 2023

Abstract Background CSF-soluble platelet-derived growth factor receptor beta (sPDGFRβ) is closely associated with pericyte damage. However, the changes in CSF sPDGFRβ levels and their role blood – brain barrier (BBB) leakage at different stages of Alzheimer’s disease (AD), or without cerebral small vessel (CSVD) burden, remain unclear. Methods A total 158 individuals from China Aging Neurodegenerative Disorder Initiative cohort were selected, including 27, 48, 83 a clinical dementia rating (CDR) score 0, 0.5, 1 2, respectively. tau, phosphorylated tau181 (p-tau181), Aβ40, Aβ42 measured using Simoa assay. Albumin by commercial assay kits. CSVD burden was assessed magnetic resonance imaging. Results highest level CDR 0.5 group. significantly correlated CSF/serum albumin ratio (Q-alb) 0–0.5 group ( β = 0.314, p 0.008) but not 1–2 − 0.117, 0.317). In group, exhibited significant mediating effect between Aβ42/Aβ40 Q-alb 0.038). Q-alb, rather than sPDGFRβ, showed difference burden. Furthermore, higher subjects progressive mild cognitive impairment those stable < 0.001). Meanwhile, yearly MMSE scores 0.400, 0.020) (A+) subgroup 0.542, 0.019). Conclusions We provide evidence that increased BBB early stage AD, which may contribute to AD progression.

Language: Английский

Citations

23
Neuronal ApoE4 in Alzheimer’s disease and potential therapeutic targets DOI Creative Commons
Lan Zhang, Yiyuan Xia,

Yuran Gui

et al.

Frontiers in Aging Neuroscience, Journal Year: 2023, Volume and Issue: 15

Published: June 2, 2023

The most prevalent genetic risk factor for Alzheimer’s disease (AD) is Apolipoprotein E (ApoE), a gene located on chromosome 19 that encodes three alleles (e2, e3, and e4) give rise to the ApoE subtypes E2, E3, E4, respectively. E2 E4 have been linked increased plasma triglyceride concentrations are known play critical role in lipoprotein metabolism. prominent pathological features of AD mainly include senile plaques formed by amyloid β (Aβ 42 ) aggregation neuronal fibrous tangles (NFTs), deposited composed Aβ hyperphosphorylation truncated head. In central nervous system, protein primarily derived from astrocytes, but also produced when neurons stressed or affected certain stress, injury, aging conditions. ApoE4 induces tau pathologies, leading neuroinflammation damage, impairing learning memory functions. However, how mediates pathology remains unclear. Recent studies shown may lead greater neurotoxicity, which increases development. This review focuses pathophysiology explains deposition, mechanisms hyperphosphorylation, potential therapeutic targets.

Language: Английский

Citations

23
Pathophysiology characterization of Alzheimer’s disease in South China’s aging population: for the Greater-Bay-Area Healthy Aging Brain Study (GHABS) DOI Creative Commons
Zhen Liu,

Dai Shi,

Yue Cai

et al.

Alzheimer s Research & Therapy, Journal Year: 2024, Volume and Issue: 16(1)

Published: April 16, 2024

Abstract Introduction The Guangdong-Hong Kong-Macao Greater-Bay-Area of South China has an 86 million population and faces a significant challenge Alzheimer’s disease (AD). However, the characteristics prevalence AD in this area are still unclear due to rarely available community-based neuroimaging cohort. Methods Following standard protocols Disease Neuroimaging Initiative, Healthy Aging Brain Study (GHABS) was initiated 2021. GHABS participants completed clinical assessments, plasma biomarkers, genotyping, magnetic resonance imaging (MRI), β-amyloid (Aβ) positron emission tomography (PET) imaging, tau PET imaging. cohort focuses on pathophysiology characterization early detection Greater Bay Area. In study, we analyzed Aβ 42 /Aβ 40 (A), p-Tau 181 (T), neurofilament light, GFAP by Simoa 470 Chinese older adults, 301, 195, 70 had MRI, PET, respectively. Plasma hippocampal volume, temporal-metaROI cortical thickness were compared between normal control (NC), subjective cognitive decline (SCD), mild impairment (MCI), dementia groups, controlling for age, sex, APOE-ε4 . A/T profiles positivity also determined different diagnostic groups. Results aims, study design, data collection, potential applications summarized. SCD individuals significantly higher than NC individuals. MCI patients showed more abnormal changes all biomarkers frequencies A+/T+ (NC; 5.9%, SCD: 8.2%, MCI: 25.3%, dementia: 64.9%) (NC: 25.6%, 22.5%, 47.7%, 89.3%) reported. Discussion may provide helpful guidance toward designing community cohorts China. This first time, reported atrophy, AD-signature thinning, as well Area These findings novel insights into understanding pathological China’s population.

Language: Английский

Citations

9
Amyloid-β oligomers drive amyloid deposit and cascaded tau pathology of Alzheimer's disease in aged brains of non-human primates DOI

Zhengxiao He,

Wenchang Zhang, Ping Chen

et al.

Journal of genetics and genomics/Journal of Genetics and Genomics, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 1, 2025

Language: Английский

Citations

1
Diagnostic value of isolated plasma biomarkers and its combination in neurodegenerative dementias: A multicenter cohort study DOI Creative Commons
Yi Chen, Yunyun Wang, Qing‐Qing Tao

et al.

Clinica Chimica Acta, Journal Year: 2024, Volume and Issue: 558, P. 118784 - 118784

Published: April 6, 2024

Plasma amyloid-β (Aβ), phosphorylated tau-181 (p-tau181), neurofilament light (NfL) and glial fibrillary acidic protein (GFAP) potentially aid in the diagnosis of neurodegenerative dementias. We aim to conduct a comprehensive comparison between different biomarkers their combination, which is lacking, multicenter Chinese dementia cohort consisting Alzheimer's disease (AD), frontotemporal (FTD), progressive supranuclear palsy (PSP). enrolled 92 demented patients [64 AD, 16 FTD, 12 PSP with dementia] 20 healthy controls (HC). Their plasma Αβ, p-tau181, NfL, GFAP were detected by highly sensitive-single molecule immunoassays. Αβ pathology was measured cerebrospinal fluid or/and amyloid positron emission tomography. All tested significantly altered compared HC, especially Aβ42/Aβ40 NfL showed significant performance distinguishing AD from HC. A combination Aβ42/Aβ40, could discriminate FTD or well HC able distinguish non-AD (FTD/PSP). Our results confirmed diagnostic individual noted that these may be more accurate identifying FTD/PSP dementia.

Language: Английский

Citations

6